Selected data models

You must log in to select data models for download or further analysis.

10 Search results.
Relevance Rating New first Old first

Hypofractionation for Breast Cancer NCT01948726 - Eligibility Criteria

- 6/15/19 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01948726 Hypofractionation with simultaneous integrated boost has been investigated in a few trials and appears to be safe and feasible with less lung toxicity in smaller studies. Investigators initiated this multicenter phase II prospective trial to analyse acute toxicity of hypofractionation with simultaneous integrated boost in patients with early breast cancer under the hypothesis that the ratio of patients with acute radiogenic toxicity Grad II according NCI-CTCAE amounts maximum 20%.

Eligibility Breast Cancer NCT00897702

- 2/22/17 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00897702

Breast Cancer Radiation Therapy Report NSABP B-36 NCT00087178 - Radiation Therapy Report Breast Cancer NCT00087178

- 5/20/15 - 1 form, 4 itemgroups, 17 items, 1 language
Itemgroups: Header, Radiation therapy, Whole Breast Irradiation, Chest Wall Irradiation
NSABP Protocol B-36 Radiation Therapy Report Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer NCT00087178 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=C87B5190-AA07-59CE-E034-0003BA12F5E7

Breast Cancer NCT01272037 Treatment - S1007 Radiation Therapy Form (S1007RAD) - 3139641v1.0 - S1007 Radiation Therapy Form (S1007RAD)

- 1/9/15 - 1 form, 6 itemgroups, 30 items, 1 language
Itemgroups: Header Module, Radiation Therapy, Site Irradiated, Targeted Regions of Treatment, Partial Breast Irradiation Method, Comments
S1007 Radiation Therapy Form (S1007RAD) Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=90C9DFFB-2367-84DB-E040-BB89AD437DC2

Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308 - Screening - Prior Ovarian Cancer Treatment; Laboratory Tests; Lesion Assessment Record

- 8/23/19 - 1 form, 13 itemgroups, 48 items, 1 language
Itemgroups: Administrative, Prior Ovarian Cancer Treatment - Chemotherapy, Has the patient received radiotherapy?, Prior Ovarian Cancer Treatment - Radiotherapy , Has the patient received prior cancer-related surgery?, Prior Ovarian Cancer Treatment - Surgical Treatment , Has the patient received other cancer-related treatments?, Other Cancer Related Treatments, Laboratory Tests (within 7 days prior to Day 1) - Haematology, Laboratory Tests (within 7 days prior to Day 1) - Haematology , Laboratory Tests (within 7 days prior to Day 1) - Chemistry, Laboratory Tests (within 7 days prior to Day 1) - Chemistry , Lesion Assessment Record
Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer

CALGB: ADJUVANT RADIOTHERAPY REPORT FORM 2 NCT00041119

- 6/21/15 - 1 form, 3 itemgroups, 16 items, 1 language
Itemgroups: Header, Patient demographics, Radiation Treatment
CALGB: ADJUVANT RADIOTHERAPY REPORT FORM 2 NCT00041119 Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=E03851EE-EEDC-5498-E034-0003BA12F5E7

CALGB: ADJUVANT RADIOTHERAPY REPORT FORM NCT00024102

- 6/3/15 - 1 form, 4 itemgroups, 16 items, 1 language
Itemgroups: CALGB Information, Patient clinical trial data, Radiation Treatment, CCRR MODULE
CALGB: ADJUVANT RADIOTHERAPY REPORT FORM NCT00024102 Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A50C8257-093C-33B9-E034-080020C9C0E0

CALGB: 49808 RADIOTHERAPY REPORT FORM NCT00016276

- 6/3/15 - 1 form, 4 itemgroups, 25 items, 1 language
Itemgroups: CALGB clinical trial administrative data, Patient clinical trial data, RADIATION TREATMENT, Comments
CALGB: 49808 RADIOTHERAPY REPORT FORM NCT00016276 Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9E35395C-8724-227A-E034-080020C9C0E0

NCT00103181 NSABP Protocol B-39 Radiation Therapy Report for Patients Randomized to PBI (Group 2 Patients Only)

- 7/5/15 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Header, Radiation Therapy Report
NCT00103181 NSABP Protocol B-39 Radiation Therapy Report for Patients Randomized to PBI (Group 2 Patients Only) Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=E74A3E53-F9E9-58E3-E034-0003BA3F9857

NSABP Protocol B-35 Radiation Therapy Report NCT00053898

- 6/3/15 - 1 form, 4 itemgroups, 19 items, 1 language
Itemgroups: Header Module, adjuvante radiatio status, Breast, Operative Area Boost
NSABP Protocol B-35 Radiation Therapy Report NCT00053898 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A01A1AE7-8AF7-36F3-E034-080020C9C0E0

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial